Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high38.00 25/04/16
52 week low19.00 01/03/16
52 week change 2.00 (6.45%)
4 week volume578,905 04/09/16

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
08/07/2014

Latest NewsMore

Broker Forecast - N+1 Singer issues a broker note on Synairgen PLC

N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...

Synairgen widens H1 pretax loss

Synairgen has widened its H1 pretax loss to 1.7m, from a year-earlier loss of 1.0m. Revenue was nil, from 25,000. "We are ve...

Interim results for six months ended 30 June 2016

RNS Number: 5051K Synairgen plc 22 September 2016 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2016 ~ Clinical development of AZD9412 with AstraZeneca on track and Pharmaxis collaboration progressing towards the clinic ~ Southampton, UK - 22 September 2016: Synairgen plc (LSE: SNG), the respir...

Notice of Interim Results

RNS Number: 2364J Synairgen plc 08 September 2016 PRESS RELEASE 8 September 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Notice of Interim Results Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its interim results for the six-month period ended 30 June 2016 o...

Result of AGM

RNS Number: 1527B Synairgen plc 14 June 2016 PRESS RELEASE 14 June 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Result of Annual General Meeting Southampton, UK, 14 June 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting...

Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?

Junior pharmaceutical stocks have the potential to create huge value for shareholders if successful. These two stocks both h...

Posting of Annual Report and Notice of AGM

RNS Number: 4029Y Synairgen plc 17 May 2016 PRESS RELEASE 17 May 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Southampton, UK, 17 May 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 16 May 2016 it posted its full Audited Report and Accounts for the twelve months ended 31 Decem...

Holding(s) in Company

RNS Number: 9600V Synairgen plc 21 April 2016 Synairgen plc ('Synairgen' or the 'Company') Holding in Company Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it received notice on 20 April 2016 that Leonard Licht, a private investor, holds 2,775,000 ordinary shares of 1 pence each in the capi...

Fundamental DataMore

EPS-2.47
Dividend yield0 %

Equity Research (SNG)

edison investment research
Synairgen
14/07/2014
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...

Latest discussion posts More

Users' HoldingsMore

Users who hold Synairgen also hold..
BENCHMARK HLDS15%
VECTURA15%
ANGLE15%
TRAKM8 HLDGS15%
RENEURON15%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG